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Abstract
The global pandemic of coronavirus disease-2019 (COVID-19) has led to significant dis-
ruptions in healthcare delivery. Patients with chronic liver diseases require a high level
of care and are therefore particularly vulnerable to disruptions in medical services during
COVID-19. Recent data have also identified chronic liver disease as an independent risk
factor for COVID-19 related hospital mortality. In response to the pandemic, national
and international societies have recommended interim changes to the management of pa-
tients with liver diseases. These modifications included the implementation of telehealth,
postponement or cancelation of elective procedures, and other non-urgent patient
care-related activities. There is concern that reduced access to diagnosis and treatment
can also lead to increased morbidity in patients with liver diseases and we may witness a
delayed surge of hospitalizations related to decompensated liver disease after the
COVID-19 pandemic has receded. Therefore, it is paramount that liver practices craft a
comprehensive plan for safe resumption of clinical operations while minimizing the risk
of exposure to patients and health-care professionals. Here, we provide a broad roadmap
for how to safely resume care for patients with chronic liver disease according to various
phases of the pandemic with particular emphasis on outpatient care, liver transplantation,
liver cancer care, and endoscopy.
Introduction
The global pandemic of coronavirus disease-2019 (COVID-19),
caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), has overwhelmed health-care systems in many
countries and led to significant disruptions in care delivery. The
burden of chronic liver diseases including hepatitis B, hepatitis
C, alcoholic liver disease, and non-alcoholic fatty liver disease
has been increasing around the world.1 Patients with chronic liver
diseases need a high level of care and are therefore particularly
vulnerable to disruptions in medical services during COVID-19,
either directly or indirectly.1 For instance, a recent analysis of na-
tional transplant databases from France and the USA showed a
striking reduction in liver transplantation during the COVID-19
era.2 Furthermore, another study conducted across the Veterans
Health Administration showed a significant decrease in hospital
admissions related to cirrhosis during this pandemic.3 Chronic
liver disease has also been identified as an independent risk factor
for COVID-19-related hospital mortality in recent studies, includ-
ing data from the COVID-Hep.net and SECURE-Cirrhosis
registries.4–6
In response to the pandemic, national and international societies
have recommended interim changes to the management of patients
with liver diseases, including the American Association for the
Study of Liver Diseases (AASLD),7,8 the British Society of
Gastroenterology,9 the European Association for the Study of the
Liver (EASL),10 and the Gastroenterological Society of
Australia.11 These modifications included the transition of a large
number of outpatient clinic visits to telemedicine, postponement
or cancelation of elective procedures, and other non-urgent patient
care-related activities. There is significant concern that even re-
strictions on routine medical care can be detrimental, as reduced
access to diagnosis and treatment can lead to increased morbidity
in patients with liver diseases.12 Multiple experts have warned that
health-care facilities could witness a delayed surge of hospitaliza-
tions related to decompensated liver disease, after COVID-19 has
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receded. Hence, liver practices must craft a comprehensive plan
for safe resumption of clinical operations while minimizing the
risk of exposure to patients as well as medical staff.
Phases of the pandemic
COVID-19 has had a worldwide impact, but there are significant
geographical differences in the burden and temporal trends of the
pandemic. Broadly, the World Health Organization categorizes
the COVID-19 pandemic into five phases, namely, acceleration,
peak, deceleration, post-peak, and post-pandemic phases.13
Countries such as China, South Korea, New Zealand, Australia,
Spain, and Italy are currently in the post-peak phase, whereas large
swathes of the USA remain either in the acceleration or decelera-
tion phase of the pandemic. Most recommendations from interna-
tional societies have discussed specific strategies for care delivery
in the context of the “acceleration” or “peak” phase. However, as
regions move across the pandemic phases, we need a plan to
reintroduce routine healthcare in a safe and timely manner during
the post-peak phases. Additionally, we need to lay the groundwork
to ramp up preparedness for future pandemics during the
post-pandemic phase, while simultaneously remaining vigilant
for further surges of cases of COVID-19 cases that may emerge.
In this review, we discuss broad principles applicable to reopening
care for patients with liver diseases with a specific reference to the
various phases of the pandemic (Figure 1).
General considerations in the care of
patients with chronic liver disease
As an international group of liver physicians, our collective expe-
rience makes it clear that a one-size-fits-all approach will not work
given the tremendous variation in patterns of care delivery around
the world. We discuss here some general recommendations which
can hopefully be adopted and modified to suit local practice pref-
erences. Before any consideration to restarting in-person care,
practices need to effectively communicate and coordinate with
local public health officials to gather information on the local
FIGURE 1 Proposed care model during different phases of the pandemic. ALF, acute liver failure; COVID-19, coronavirus disease-2019; HCC, hepa-
tocellular carcinoma; MELD, model for end-stage liver disease. [Color figure can be viewed at wileyonlinelibrary.com]
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status of the pandemic. Once they have confirmed sustained
regional decelerations or entry into the post-peak phase,
health-care facilities can plan to safely resume non-COVID-19
care. Moreover, health-care systems have to be agile and be pre-
pared to transition back to mitigation efforts if public health
officials report a local surge in cases.
During the acceleration and peak phases of the pandemic, most
practices have switched in-person care to telehealth. Telehealth is
both patient-centered and conducive to social isolation practices
with provider–patient communication methods ranging from
phone calls to smartphone apps or webcam enabled computers.14
Telehealth will likely continue to play a prominent role in the care
of patients with liver diseases during the deceleration phase. We
suggest a stepwise approach using telehealth as a buffer while
we increase the capacity for face-to-face visits. which are clinically
indicated. During the initial step, patients with a need for in-person
visits should be scheduled in the clinic, which may comprise 25–
50% of clinic sessions, and telehealth continued for all other pa-
tients. In the subsequent step, most patients can come back for
in-person visits in the clinic, but telehealth should continue to be
offered for those with stable disease and those who prefer to con-
tinue to use this modality. In the end, the proportion of sessions
that can be indefinitely repurposed as telehealth visits should be
decided by individual clinics. All clinical practices need to develop
their own best practice guidelines outlining how physical distanc-
ing will be maintained and how clinical staff will use personal pro-
tective equipment (PPE) during in-person visits. These guidelines
will likely need to be refined throughout the pandemic. It is also
important to develop local policies for how patients who are un-
dergoing high-risk procedures, like endoscopy, will be screened
for COVID-19 before arrival either via point of care polymerase
chain reaction (PCR) testing or symptom-based questionnaires.
To facilitate this, we propose a system that implements a triage
for symptoms 24–48 h prior to visit, the continued surveillance
for COVID-19 among symptomatic patients and mandatory tem-
perature checks for both staff and patients. Inpatient settings have
to be prepared for a possible surge of non-COVID-19-related
admissions, and they need to isolate the COVID-19 patients from
the other patients. Designating hospital areas into either
COVID-19 zones or non-COVID-19 zones has been suggested
as one of the measures that can minimize exposure for both pa-
tients and staff.15 In addition, the following steps can be adopted
to maintain social distancing in the clinic such as electronic
check-in and check-out processes, staggered staff schedules, uni-
versal masking for everyone inside health-care facilities, and
limiting family members and patient visitors. These infection
prevention and control policies should be continued regardless of
the pandemic phase.
Resuming in-person outpatient clinical
care
Routine outpatient care was significantly impacted during the on-
set of COVID-19. When practices resume in-person clinic visits,
they need to ensure they are following appropriate screening prac-
tices for COVID-19 and also enforce adequate social distancing in
the liver clinic. Given these new requirements, it is likely that the
number of patients who can be seen in-person will not immedi-
ately reach pre-pandemic levels, once outpatient clinical care is
reopened. Clinical practices need to develop a strategic framework
to identify and prioritize patients who need in-person visits earlier.
During the deceleration phase, and to an even greater extent dur-
ing the post-peak period, we urge physicians to work closely with
the liver clinic administrative staff to identify patients with ad-
vanced chronic liver diseases whose visits were either canceled
or postponed during the pandemic and to ensure these patients
are not lost to follow up. Additionally, a comprehensive review
of the clinic backlog should be performed, with earlier scheduling
of patients based on disease severity and clinical need. Symptom-
atic patients, patients with hepatic decompensation, those whose
liver tests are worsening, or patients with liver cancer should be
prioritized to be brought back to the clinic sooner, while routine
follow up of patients with stable liver disease from hepatitis B or
non-alcoholic steatohepatitis can be slightly delayed (Table 1).
Special attention needs to be given for liver cancer patients who
have received locoregional therapy, which represents a heteroge-
nous group, and optimal follow up and rescheduling should be
considered in the context of a multidisciplinary team. This review
should include new patient consults and also secure early outpa-
tient follow up of patients recently discharged from the hospital.
A proposed general schema is as follows:
a Priority 1—needs to be seen right away; examples include
patients who are decompensated that have not been stabi-
lized, listed for liver transplant, newly diagnosed with liver
cancer, and under consideration of resection or recent
locoregional therapy.
b Priority 2—can be delayed by 2–3 months; examples of
which include patients who are decompensated but on sta-
ble doses of medication, treatment-naïve HCV patients.
c Priority 3—can be delayed by 3–6 months; examples of
which include patients with compensated cirrhosis without
ongoing liver injury, patients with hepatitis C cirrhosis who
have achieved sustained virologic response, chronic hepati-
tis B on treatment, newly diagnosed non-alcoholic fatty
liver disease or non-alcoholic steatohepatitis patients.
Table 1 A suggested framework for prioritizing visits
In-person visits
General hepatology clinic
Patients with decompensated cirrhosis
Patients requiring active adjustment of medications (diuretics,
encephalopathy medications)
Pre-transplant evaluations
Patients with alcohol-related liver disease who restart drinking
Evaluation for elevated liver enzymes >3 times upper limit of normal
Hepatitis C treatment
Consider for patients with advanced fibrosis/cirrhosis
Hepatocellular carcinoma
Initial diagnostic evaluation
Case-by-case consideration for patients with autoimmune hepatitis,
Wilson’s disease, etc. requiring more urgent clinic evaluation
Continue telehealth
Routine visits for compensated cirrhosis
Hepatitis C treatment for patients without advanced fibrosis/cirrhosis
Evaluation for elevated liver enzymes <3 times upper limit of normal
Initial evaluation of non-alcoholic fatty liver disease
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d Priority 4—can be delayed by 6–9 months; examples of
which include patients with or without cirrhosis seen in
the last 6 months, patients with hepatitis C who have
achieved sustained virologic response, stable
non-alcoholic fatty liver disease, early stage primary biliary
cholangitis, or primary sclerosing cholangitis with stable
liver chemistries.
Another issue that needs to be addressed as part of the reopening
is maintenance of continuity of care. During the pandemic, many
liver physicians were deployed to other areas of need in the
health-care system, such as emergency rooms and COVID-19 ded-
icated wards, while selected colleagues saw their patients in the
liver clinic. Ideally, patients should be reassigned to their
pre-pandemic care providers to maintain continuity in the
patient–provider relationship.
Assessing the degree of fibrosis is an important aspect in the
care of patients with chronic liver disease and practices need to ju-
diciously resume the use of ancillary testing such as transient
elastography (TE) to determine fibrosis score. TE such as
FIbroScan® is typically performed in the office, by the consulting
hepatologist or an advanced provider and involves close contact
with patients. While it is considered to be safe to resume
in-clinic TE in the deceleration or post-peak phases of the pan-
demic, providers need to wear appropriate PPE throughout the
procedure.16 This should be according to local infection preven-
tion and control policies and at a minimum should include surgical
face masks for both the patient and care provider and disposable
gloves. Even with appropriate precautions, TE is still associated
with risk for exposure to SARS-Co-V2, given the close proximity
to the patient, duration of contact with patient, and unknown ade-
quacy of current disinfection protocols for transducer probes.
Hence, it is important to continue to limit the use of TE where al-
ternative non-invasive robust markers for fibrosis such as FIB-4,
AST to platelet ratio index, or non-alcoholic fatty liver disease fi-
brosis score are available.12
With appropriate planning and implementation, we can hope-
fully restore adequate levels of outpatient care for patients with
chronic liver disease in a timely manner. We propose a general
strategy for in-person visit prioritization in Table 1, which can be
adopted and modified to fit institutional and provider preferences
(Figure 1).
Liver transplantation: Considerations
during the coronavirus disease-2019 era
Patients requiring liver transplantation have been disproportion-
ately affected by the pandemic as living donor programs have
come to a halt in many countries and rates of deceased donor liver
transplantation have plummeted.2 During the acceleration and
peak phases of the pandemic, liver transplantation evaluations
were paused for non-urgent indications. Several recommendations
have been made for screening recipients and donors for
COVID-19 by the various international transplant societies to
ensure the safety of patients and medical staff. Furthermore, the
role of immunosuppression in disease severity remains
controversial,17,18 leading to wide variations in how hepatologists
manage post-transplant patients. We will discuss the care of
patients with chronic liver disease with relation to liver
transplantation in three separate parts—pre-transplant evaluation,
transplant surgery, and post-transplant management.
Pre-transplant evaluation. During the deceleration and
the post-peak phases of the pandemic, transplant centers will look
to ramp up transplant evaluation and listing. Although some as-
pects of transplant evaluation are feasible via telehealth and using
local laboratories, the face-to-face interaction with the surgery
team, social worker, and hepatologist is of utmost value. It is im-
portant for centers to decide which aspects of transplant evaluation
could continue via telehealth in the post-peak phase. For example,
psychosocial evaluation, nutritional assessment, social work eval-
uation, or visit with pharmacists can all be achieved via telehealth,
even more efficiently, as multiple providers do not have to be pres-
ent in a single space during the evaluation. For now, it is still best
to take a stepwise approach and continue to do as much telehealth
as possible. One of the most important steps before fully opening
up in-person clinics is to work with local officials to understand
the COVID-19 local incidence, capacity for testing, and local man-
dates for isolation.
It has been recommended that transplant offers should be
limited to patients with a high model for end-stage liver disease
score, patients with hepatocellular carcinoma (HCC) close to
Milan criteria limit, and those with acute liver failure during the
acceleration and peak phases of the pandemic.7,11,19 This approach
should be continued until there is a sustained local decrease in the
number of COVID-19 cases for at least 14 days. At that point, cen-
ters should consider broadening the transplantation criteria. How-
ever, we have to remain vigilant and anticipate further surges of
COVID-19 cases, with a plan to reenter mitigation efforts and
scale back transplantation as needed.
Rapid testing for COVID-19 by real-time PCR should be con-
tinued for all patients who are high on the waiting list. There is a
lack of understanding as to whether transmissibility decreases after
resolution of COVID-19 and if viral shedding directly implies
transmissibility. This will make it challenging to triage patients
who test positive for SARS-CoV-2 but are otherwise suitable can-
didates for transplant. In one study, patients were retested in 8 days,
and if negative, the transplant team proceeded with reactivation of
the transplantation waiting list.20 Because patients can shed virus
for many more days without symptoms, negative PCR seems a
reasonable approach prior to activation on the list.
Transplant surgery. Most elective surgeries including liver
transplantation and hepatic resections for cancer have seen a de-
cline in numbers during the COVID-19 pandemic, as shown by
an Italian survey.21 In the USA, the Center for Medicare and Med-
icaid Services designated deceased donor liver transplantation as a
tier 3b procedure, putting it in the “do not postpone” category.
Despite this designation, there was a significant drop in both de-
ceased donor and living donor liver transplantation in the USA
and also in most parts of the world.2 The main aim of developing
reopening strategies is to safely restore the numbers of liver trans-
plantation back to pre-COVID-19 levels. These efforts largely de-
pend on the stage of the pandemic, which in turn determines
availability of resources and feasibility to safely proceed with
transplantation.
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A recent autopsy study showed high SARS-CoV-2 viremia in
60%, and very high viral titers in the liver in 41% of the patients
who died of severe COVID-19.22 Hence, the recommendations
to avoid donors diagnosed with COVID-19 are prudent.23 To en-
sure that organs from asymptomatic donors who are SARS-CoV-
2 positive do not inadvertently get accepted, it is important to
screen donors for COVID-19. Donors should be screened by epi-
demiological and clinical history for suspected COVID-19 as well
as PCR within 3 days of procurement, when feasible. Currently,
the American Society of Transplantation advises against using
chest computed tomography (CT) to screen asymptomatic living
donors for COVID-19 although several centers around the world
include CT chest in the preoperative evaluation because living do-
nors undergo CT of the liver as a part of surgical planning anyway.
Preventative strategies and social distancing measures should be
reinforced in living donors, especially within 14 days prior to
planned organ donation. If a living donor is considered high risk
either because of COVID-19 symptoms or exposure, organ dona-
tion should be postponed by at least 28 days. In case of donors
at intermediate risk for COVID-10 like those with exposure but
no symptoms, American Society of Transplantation recommends
we consider delaying the transplant for at least 14 days.24 If the do-
nor risk for COVID-19 is confirmed to be low based on clinical
and epidemiological criteria, one can consider proceeding with
transplantation even without PCR testing. Moreover, if the donor
has had resolution of symptoms more than 28 days prior to organ
donation and has negative testing repeated at least 24 h apart, or-
gans are considered safe to use.24
Current recommendations do not endorse SARS-Co-V2 anti-
body testing for donor screening, given the unreliable results.24
Rapid antigen testing approved by the Food and Drug Administra-
tion in early May is also not recommended for donor screening. A
case report published recently discussed the clinical course of a
living liver donor who was mildly symptomatic prior to donor
hepatectomy tested positive on postoperative day 3 and subse-
quently improved without much trouble. We do need more data
about the safety of hepatectomy in asymptomatic COVID-19
patients.25
There are limited published data on the early experience with
liver transplantation during the COVID-19 era. A report from the
hyperendemic region in Italy noted that 2 of the 17 patients who
underwent liver transplantation developed COVID-19 on postop-
erative days 9 and 22.26 Whether the infections were nosocomial,
donor-derived or just delayed diagnosis of asymptomatic recipi-
ents could not be ascertained conclusively. On the other hand, a
center in Sichuan, China, reported no complications in the six liver
transplants performed during COVID-19.27 They also reported
using standard immunosuppression without dose reduction. The
only caveat was the level of spread in that province was not very
high. Most of the centers have already adopted real-time-PCR
and CT scan screening along with serology to rule out asymptom-
atic infection in donors, but unless we completely isolate the trans-
plant process from cross-contamination and are able to identify all
asymptomatic COVID-19 patients, the levels of transplantation
may not reach the pre-COVID19 era any time soon.
Post-transplant care. Post-transplant patients represent a
high-risk group in the COVID-19 era because there is significant
concern that the ongoing immunosuppression makes them more
vulnerable to acquire SARS-CoV-2; hence, efforts to isolate them
from exposure to the virus must continue. Ideally, the location of
the clinic and the medical team taking care of pre-transplant and
post-transplant patients should be segregated from one another.
Measures that can be taken to minimize exposure risk are similar
to pre-transplant care and include offering telemedicine for follow
up, using local laboratories for blood tests, and providing medica-
tion refills through the mail. Patients in the immediate
post-transplant phase need close follow up and frequent blood
tests. One approach is to continue frequent blood work for up to
1-month post-transplant, and then to space out blood tests to every
2 weeks followed by every 4 weeks and eventually transition to
every 3–6 months post-transplant. This has to be individualized
on a case-by-case basis depending on the patient’s overall clinical
condition.
Most expert guidelines have recommended that patients con-
tinue their stable doses of immunosuppression and warn against
reductions in immunosuppression during COVID-19 pandemic.
In patients with severe COVID-19, steroids need to be avoided if
possible and immunosuppression minimized to lowest safe doses.
In the post-peak phase, transplant hepatologists need to make sure
that all post-transplant patients are on adequate doses of
immunosuppression in order to avoid unwanted complications like
acute rejection.
Care of patients with hepatocellular
carcinoma
Patients with liver cancer face the dilemma of either being exposed
to a higher risk of COVID-19-related mortality if they continue
medical care versus a higher risk of cancer-related mortality if care
is disrupted. Patients with an underlying diagnosis of cancer are
increasingly being reported to experience more severe
COVID-19 infections and higher mortality if infected.28–30 Most
clinical practices have tried to continue to provide uninterrupted
care for patients with liver cancer during COVID-19 by embracing
telemedicine. The uniform recommendations from AASLD,
EASL, and the International Liver Cancer Association have been
to continue imaging surveillance, to maintain virtual multidisci-
plinary tumor boards, and to sustain transarterial therapies and sys-
temic therapies as indicated.7,31
In reality, despite our best efforts, several aspects of clinical care
will undoubtedly be interrupted for patients with liver cancer. For
instance, elective surgical procedures like liver resection and ther-
mal ablation have been canceled or rescheduled. Although only a
select group of patients who present with single, small tumors
are generally eligible for these, there is significant concern that
postponing these procedures could have led to progression of can-
cer and these patients subsequently could become ineligible for
curative procedures. When reopening care, every effort must be
made to quickly reschedule these elective procedures for eligible
patients with HCC. Liver transplant evaluation or listing might
have been delayed for patients with liver cancer who are
candidates for transplant. In the post-peak phase, these patients
should be prioritized to undergo expedited transplant listing be-
cause they already have extended wait times before they can avail
exception points. It is likely that transarterial therapies like
chemoembolization or radioembolization were continually offered
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during the COVID-19 peak in most practices. If there were any in-
terruptions either because of patient cancelations or limitations in
access, these therapies have to be expeditiously resumed to avoid
cancer progression.
Radiology departments are expected to experience a surge in
need for imaging services once routine care resumes. All patients
with HCC whose surveillance imaging had been postponed will
need to be prioritized when the radiology division opens up, to en-
sure we can monitor tumor response to therapy and decide upon
appropriate next steps. Moreover, surveillance ultrasound scans
for patients with cirrhosis have also been rescheduled based on
current recommendations from international societies. Patients
whose procedures were postponed need to be sent appropriate re-
minders to ensure they attend their new appointments and do not
miss these crucial tests needed for early detection of HCC. In case
of limited availability of radiologic testing for HCC surveillance,
we suggest prioritizing patients with a high risk of HCC, including
those with Liver Imaging Reporting and Data System 3/4 lesions
on previous imaging, patients on the transplant list, and patients
who have not had regular previous surveillance. Finally, clinical
trial enrolment for patients with advanced HCC has been signifi-
cantly impacted because most centers interrupted clinical trial en-
rolment during the peak of COVID-19.32 Strategic planning and
coordination will be needed to ensure robust enrolment of patients
with advanced HCC in ongoing clinical trials once we reopen rou-
tine care in the post-peak and post-pandemic phases of COVID-
19.
Resuming endoscopy after coronavirus
disease-2019
During the acceleration and peak phases of the COVID-19 pandemic,
most endoscopy activity has been suspended except for urgent, life
threatening conditions and time-sensitive cases.33–36 Elective proce-
dures specific to patients with liver diseases that may have been
deferred include esophagogastroduodenoscopy for variceal screening
and endoscopic retrograde cholangiopancreatography for dilatation
or stent replacement in post-liver transplantation or primary scleros-
ing cholangitis.19 As the tide of the pandemic turns, a stepwise,36
phased37 resumption of elective endoscopy services will need to be
implemented with strategies to ensure that deferred endoscopies
are tracked.
Recently, various societies have offered guidance on resuming
elective endoscopies. The joint American Gastroenterological
Association/Digestive Health Physicians Association guidance38
specifically mentions the importance of abiding by local authori-
ties’ guidance when considering the timing and approach to
reopening. Scheduled endoscopies should continue to be
prioritized by level of urgency, based on individual patient
considerations and physician’s judgment. The American Society
for Gastrointestinal Endoscopy recommends prioritizing into three
tiers, urgent (tier 1), semi-urgent (tier 2), and elective (tier 3).39
Strict screening procedures may prevent the spread of
COVID-19 via digestive endoscopy during this period.40,41 The
concept of a “shielded” category of patients who are essentially
immunocompromised and require more protection is advocated
by the British Society of Gastroenterology guidance.37 It is sug-
gested that all patients should receive PCR-based testing for active
COVID-19 infection wherever possible,37–39 and if not feasible,
then patients should keep a daily temperature log for 10 days prior
to the procedure. A symptom questionnaire and temperature check
should be administered to all patients on the day of procedure. Of
note, many of the protective measures with regard to infection pre-
vention and control are kept in force with mask recommendations
based on the availability of PCR-based COVID-19 testing and
PPE supplies.38 Although, less flexibility is allowed by the
American Society for Gastrointestinal Endoscopy guidance, which
suggests the use of N95 respirators or equivalent regardless of
COVID-19 test results given the moderate negative predictive
value of PCR testing done on nasal swab samples and insufficient
data regarding the correlation between infectivity and antibody
development.39
Specifically for variceal screening, during the peak of COVID-
19, EASL11 recommended risk assessments by applying the
Baveno VI criteria for risk stratification, where patients with a
liver stiffness <20 kPa with a platelet count >150 000 have a very
low risk of having clinically significant varices that require treat-
ment and can avoid screening endoscopy altogether.42 The
AASLD7 goes even further to suggest primary prophylaxis with
non-specific beta blockers instead of screening endoscopy in pa-
tients with clinically significant portal hypertension or high risk
of decompensation. This is supported by a recent study where
long-term treatment with beta blockers could increase
decompensation-free survival in patients with compensated cirrho-
sis and clinically significant portal hypertension, although the ben-
efits were mainly observed for patients with ascites.43 A protocol
has been devised to help manage these patients if there is limited
access to endoscopy. In general, it is thought that the benefit of en-
doscopy outweighs the risk of COVID-19 for patients with recent
variceal bleeding and for patients with compensated and decom-
pensated cirrhosis who are intolerant to non-specific beta
blockers.44 We would like to emphasize that these recommenda-
tions are largely based on expert opinion and hence need to be
modified to suit local practice patterns.
Preparedness for post-pandemic phase
All the reopening measures need to be considered in the context of
the pandemic where the possibility of a second peak or even
further peaks is still possible. Long-term plans need to be in place
as some models project that the effects of COVID-19 may last un-
til 2022.45 Any efforts for reopening clinical services will need to
take into account the local situation regarding the outbreak and
allow for the flexibility to recalibrate the overall strategy. Contin-
gency plans should be established with rapid response measures in
coordination with public health officials. Factors that may need to
be reevaluated continuously include the availability of effective di-
agnostics, levels of PPE available, and future developments that
include population immunity and the availability of vaccines.
The COVID-19 outbreak has been a humbling experience for
all. In the post-pandemic phase, efforts would be shifted to prepare
for future pandemics.46,47 Measures would include the stockpiling
of PPE, medical equipment and crucial medications, developing
surge capacity within health-care systems, improving access to
telehealth services, establishing pandemic preparedness commit-
tees to develop clinical frameworks for future outbreaks,
strengthening the coalition with local public health officials, and
developing better predictive models.
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Conclusions
The COVID-19 pandemic has disrupted health-care delivery for
patients with chronic liver diseases all over the world. Fortunately,
most regions of the world are transitioning either to the decelera-
tion on post-peak phase of the COVD-19 pandemic. As we move
into these later phases of this pandemic, the resumption of normal
clinical services will become increasingly important to ensure pa-
tients receive adequate and timely care. Close liaison with local
public health authorities for coordinated strategies and having
the flexibility to adapt to the ebbs and flows of the pandemic will
be essential for the safe reopening of services. In this review, we
have provided a broad roadmap for how to safely resume care
for patients with chronic liver diseases in various clinical settings
including outpatient care, liver transplantation, and endoscopy.
We are hoping that the most grueling phases of the COVID-19
pandemic are now behind us so we can focus on rebuilding our
clinical practices. Patients with chronic liver diseases have missed
clinic appointments, surveillance ultrasounds, elective endos-
copies, laboratory tests, and even medication refills during this
pandemic. We owe these patients a comprehensive and realistic
plan to safely and expeditiously restore access to all levels of care
while minimizing their exposure to SARS-CoV-2. Lastly, we hope
that the lessons learnt from managing the current outbreak will en-
hance preparedness for future pandemics.
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